# Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis

> **NCT04854096** · PHASE2 · TERMINATED · sponsor: **NS Pharma, Inc.** · enrollment: 7 (actual)

## Conditions studied

- Primary Myelofibrosis
- Post-essential Thrombocythemia Myelofibrosis
- Post-polycythemia Vera Myelofibrosis

## Interventions

- **DRUG:** NS-018
- **DRUG:** Best Available Therapy

## Key facts

- **NCT ID:** NCT04854096
- **Lead sponsor:** NS Pharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-01-31
- **Primary completion:** 2024-05-16
- **Final completion:** 2024-05-16
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** The study was stopped due to a business decision.
- **Last updated:** 2025-05-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04854096

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04854096, "Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04854096. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*